Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

BARTSDAD, for the Vasoactive Intestinal Peptide test, normal values should be less than 70 pg/mL (20.7 pmol/L).

People with VIP-secreting tumors usually have values 3 to 10 times above the normal range.

Normal value ranges may vary slightly among different laboratories. Some labs use different measurements or test different samples.

https://www.ucsfhealth.org/medical-tests/vasoactive-intestinal-peptide-test
DIABETES IS AMONG THE TOP 10 LEADING CAUSES OF DEATH IN THE USA, FOURTH CAUSE OF DEATHS IN THE WORLD!!! Because of its broad spectrum of biological functions such as acting as a potent anti-inflammatory factor through suppression of Th1 immune response, and induction of immune tolerance via regulatory T cells, VIP has emerged as a promising therapeutic agent for the treatment of many autoimmune diseases including diabetes.

https://jme.bioscientifica.com/view/journals/jme/49/3/R157.xml
CAN WE GET A PIECE OF THIS MARKET???
Global Diabetes Therapeutics Market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023.

https://www.alliedmarketresearch.com/diabetes-therapeutics-market